<div id="readability-page-1"><div>Dublin, March 19, 2025 (GLOBE NEWSWIRE) -- The &#34;Acute Respiratory Distress Syndrome Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033&#34; report has been added to ResearchAndMarkets.com's offering.The Acute Respiratory Distress Syndrome market is expected to reach US$ 2.53 billion by 2033 from US$ 1.32 billion in 2024, with a CAGR of 7.51% from 2025 to 2033</div> <div>The increased incidence of chronic respiratory diseases, improvements in oxygen therapy and mechanical ventilation, expanding awareness of early diagnosis, and a growing need for novel treatments and individualized care are the main factors propelling the acute respiratory distress syndrome (ARDS) market.One of the main factors propelling the acute respiratory distress syndrome (ARDS) market's expansion is the increasing incidence of respiratory illnesses. The risk of ARDS is greatly increased by illnesses including pneumonia, chronic obstructive pulmonary disease (COPD), and viral infections like COVID-19.</div> <div>The number of individuals who acquire ARDS as a consequence is rising as respiratory disorders continue to rise internationally, particularly with the aging population and the expansion of infectious infections. This fuels the need for cutting-edge therapies and practical ARDS management techniques. The market has grown as a result of the need for prompt intervention and improved clinical results, with pharmaceutical companies and healthcare professionals concentrating on creating more potent treatments and solutions to treat respiratory failure brought on by ARDS.Advancements in Medical TechnologiesBecause they enhance patient care and treatment results, medical technology advancements are essential to the expansion of the ARDS market. ARDS management has advanced significantly thanks to advancements in non-invasive respiratory support devices, mechanical ventilation, and extracorporeal membrane oxygenation (ECMO). For critically ill patients, these technologies aid in providing more efficient respiratory support and oxygenation.</div> <div>While ECMO provides life-saving support for patients with severe ARDS who do not respond to standard treatments, mechanical ventilation has advanced to enable greater, more accurate control over oxygen levels and airway pressure. Additionally, non-invasive ventilation methods lessen the need for intrusive procedures, which enhances patient results and comfort. The market for ARDS treatments keeps expanding as new technologies become more widely available and utilized, improving the prognosis for ARDS patients everywhere.Increasing Healthcare AwarenessA major factor propelling the ARDS market is rising healthcare knowledge, which also helps with early diagnosis and better patient outcomes. Both medical professionals and the general public are learning more about the origins, symptoms, and available treatments of acute respiratory distress syndrome as awareness of its seriousness and possible repercussions increases. This increased awareness results in early detection, which enables timely intervention and improved condition management.</div> <div>Recovery rates are increased because medical personnel are better able to identify the symptoms of ARDS and start the right treatments earlier. The market has also grown as a result of public awareness initiatives, particularly during health emergencies like the COVID-19 pandemic, which have increased knowledge about ARDS and prompted prompt medical attention and the creation of more specialized treatments.Challenges in the Acute Respiratory Distress Syndrome Market</div> <div>Complexity of DiagnosisBecause acute respiratory distress syndrome (ARDS) can be mistaken for other respiratory diseases such sepsis and pneumonia, diagnosing it can be challenging. Early detection of ARDS is difficult because symptoms including dyspnea, low oxygen levels, and trouble breathing can be confused with a variety of other conditions. Since early care can stop the development of more severe respiratory failure, a timely and correct diagnosis is essential for improving patient outcomes.</div> <div>However, the diagnostic process frequently calls for sophisticated methods that aren't always easily accessible in all healthcare settings, like imaging, blood testing, and respiratory evaluations. The patient's condition may worsen and death rates may rise as a result of inefficient treatments brought on by this diagnosis delay.Lack of Specific TreatmentsThe absence of highly precise and focused medicines is a major obstacle in the ARDS market. There is no known cure for acute respiratory distress syndrome (ARDS), despite the widespread use of supportive therapy including mechanical ventilation and extracorporeal membrane oxygenation (ECMO). Instead, than treating the syndrome's fundamental causes, these treatments are meant to manage its symptoms.</div> Since ARDS can arise from a variety of triggers, including infections, trauma, or aspiration, the lack of a universally applicable remedy is especially troublesome. Because of this, the medical establishment still uses broad strategies that might not work as well for every patient. The potential for better results is hampered by this gap in focused medication therapy, highlighting the need for additional specialized, customized treatment alternatives. Company Analysis: Overview, Key Person, Product Analysis, Recent Development, Revenue <ul><li>Ajanta Pharma Limited</li><li>Akorn Operating Company LLC</li><li>Alembic Pharmaceutical Ltd.</li><li>Cipla Inc.</li><li>Indoco Remedies Ltd.</li><li>Johnson &amp; Johnson</li><li>Novartis AG</li><li>Ocular Therapeutix, Inc.</li><li>Sun Pharmaceutical Industries Ltd.</li><li>Teva Pharmaceutical Industries Ltd.</li></ul> <table><tbody><tr><td>Report Attribute</td><td>Details</td></tr><tr><td>No. of Pages</td><td>200</td></tr><tr><td>Forecast Period</td><td>2024 - 2033</td></tr><tr><td>Estimated Market Value (USD) in 2024</td><td>$1.32 Billion</td></tr><tr><td>Forecasted Market Value (USD) by 2033</td><td>$2.53 Billion</td></tr><tr><td>Compound Annual Growth Rate</td><td>7.5%</td></tr><tr><td>Regions Covered</td><td>Global</td></tr></tbody></table> <div>Key Topics Covered:1. Introduction2. Research &amp; Methodology3. Executive Summary 4. Market Dynamics 4.1 Growth Drivers 4.2 Challenges 4.3 Opportunities5. Global Acute Respiratory Distress Syndrome Market6. Global Acute Respiratory Distress Syndrome Market Share Analysis 6.1 By Types 6.2 By End User 6.3 By Countries7. Type 7.1 Diagnosis 7.2 Treatment8. End User 8.1 Hospitals 8.2 Specialty clinics 8.3 Home healthcare 8.4 Others9. Countries 9.1 North America 9.1.1 United States 9.1.2 Canada 9.2 Europe 9.2.1 France 9.2.2 Germany 9.2.3 Italy 9.2.4 Spain 9.2.5 United Kingdom 9.2.6 Belgium 9.2.7 Netherlands 9.2.8 Turkey 9.3 Asia Pacific 9.3.1 China 9.3.2 Japan 9.3.3 India 9.3.4 Australia 9.3.5 South Korea 9.3.6 Thailand 9.3.7 Malaysia 9.3.8 Indonesia 9.3.9 New Zealand 9.4 Latin America 9.4.1 Brazil 9.4.2 Mexico 9.4.3 Argentina 9.5 Middle East &amp; Africa 9.5.1 South Africa 9.5.2 Saudi Arabia 9.5.3 United Arab Emirates10. Porter's Five Forces Analysis 10.1 Bargaining Power of Buyers 10.2 Bargaining Power of Suppliers 10.3 Degree of Competition 10.4 Threat of New Entrants 10.5 Threat of Substitutes11. SWOT Analysis 11.1 Strength 11.2 Weakness 11.3 Opportunity 11.4 Threats12. Key Players Analysis</div> For more information about this report visit https://www.researchandmarkets.com/r/oqvvzj About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre></pre> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NTAzZjVjYTQtYTJhOS00YWNjLWFhN2MtNDNkZTkyYWMwYTRjLTEwMjY3MzctMjAyNS0wMy0xOS1lbg==/tiny/Research-and-Markets.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NTAzZjVjYTQtYTJhOS00YWNjLWFhN2MtNDNkZTkyYWMwYTRjLTEwMjY3MzctMjAyNS0wMy0xOS1lbg==/tiny/Research-and-Markets.png"/></div>

ARDS

《急性呼吸窘迫綜合症市場規模與份額分析 - 增長趨勢與 2025-2033 年預測報告》顯示，ARDS 市場預計將從 2024 年的 13.2 億美元增長到 2033 年的 25.3 億美元，年均增長率為 7.51%。主要增長驅動因素包括慢性呼吸疾病的增加、醫療技術的進步以及健康意識的提升。然而，複雜的診斷和缺乏特定治療等挑戰依然存在。報告還包括對 Ajanta、Akorn 和諾華等主要公司的分析

Acute Respiratory Distress Syndrome Market Forecast Report and Company Analysis 2025-2033 Featuring Ajanta, Akorn, Alembic, Cipla, Indoco Remedies, J&J, Novartis, Ocular Therapeutix, Sun,Teva

急性呼吸窘迫綜合症市場預測報告及公司分析 2025-2033，涉及 Ajanta, Akorn, Alembic, Cipla, Indoco Remedies, 強生公司， 諾華公司， Ocular Therapeutix, Sun 製藥， Teva 製藥

急性呼吸窘迫綜合症市場預測報告及公司分析 2025-2033，涉及 Ajanta, Akorn, Alembic, Cipla, Indoco Remedies, 強生公司，諾華公司， Ocular Therapeutix, Sun 製藥， Teva 製藥